Neuroscience

Linus Health Showcases Digital Breakthroughs to Advance Early Detection and Personalization in Brain Health at AAIC 2025

Powering Alzheimer's research with AI-driven insights across cognition, meaning, motor function, and speech — accelerating study recruitment and enabling more…

5 months ago

WorldViz Publishes New Partners in Science Report, Highlighting 730+ Peer-Reviewed Studies Using WorldViz VR

SANTA BARBARA, Calif., July 22, 2025 /PRNewswire/ -- WorldViz is excited to announce its seventh and most comprehensive Partners in…

5 months ago

Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with IXICO for the Transformative Bio-Hermes-002 Study

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementiasWASHINGTON, July 22, 2025 (GLOBE…

5 months ago

Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call

MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,…

5 months ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie’s missionCARSON CITY, Nev.,…

5 months ago

Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology

-- Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience -- -- Topline Results from RECONNECT…

5 months ago

ProMIS Neurosciences Announces Private Placement Financing

$2.4 million private financing plus an additional $6.8 million of proceeds due to exercise of warrants and $0.8 million from…

5 months ago

CORRECTING and REPLACING MedTech Innovator Unveils 64 Breakthrough Medtech Startups in its 2025 Cohort

—Top 4% of Global Applicants Selected to Compete for $800K in Non-Dilutive Funding and Unmatched Industry Access— —Up to 13…

5 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s DiseaseCAMBRIDGE, Mass., July 21,…

5 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease CAMBRIDGE, Mass., July…

5 months ago